A Consensus Emerges: Major Banks Turn Bullish on Bayer's Recovery

Leading banks raise price targets for Bayer AG, citing progress on glyphosate litigation, strong drug pipeline, and a clear path to debt reduction.

A notable shift in sentiment is underway among major financial institutions regarding the prospects for Bayer AG. Multiple leading banks have concurrently issued upgraded assessments for the German conglomerate, highlighting a growing conviction that the company may be turning a corner after years of significant challenges.

Technical and Fundamental Catalysts Align

Bayer's shares currently trade approximately 23% below their 52-week high of €49.17. This positioning, coupled with a current Relative Strength Index (RSI) reading of 20—often interpreted as a technical signal of an oversold condition—is drawing attention from market strategists. The convergence of this technical perspective with emerging fundamental improvements forms the core of the renewed analyst optimism.

Wall Street Revises Targets Upward

A cluster of prominent firms has recently refreshed their outlooks. Oddo BHF significantly raised its price objective from €39.80 to €55.00. UBS upgraded the stock to a "Buy" rating on March 16, setting a €52 target. Goldman Sachs envisions the share price reaching €54, while Barclays maintains an "Overweight" stance with a €48 target. The common thread across these evaluations is a belief in Bayer's capacity for operational recovery and a methodical reduction of its debt burden.

The Glyphosat Litigation Cloud Begins to Lift

The primary driver behind this changing narrative is the progressing resolution of the long-running glyphosate litigation. A US settlement agreement worth $7.25 billion has already received preliminary approval. The opt-out deadline is set for June 4, 2026, with a decision from the US Supreme Court expected by the end of June. A favorable final ruling would remove one of the most substantial overhangs on Bayer's financial statements, which recorded special legal provisions of around €6.0 billion in 2025 alone.

Pharmaceutical Pipeline Delivers Positive News

Concurrently, Bayer's pharmaceuticals division is providing operational encouragement. Phase III data for the kidney drug Kerendia (finerenone) demonstrated efficacy in non-diabetic patients, a substantially larger addressable population than previously targeted. Analysts now estimate the drug's peak annual sales potential to reach at least $2.6 billion.

Strong Q4 2025 and a Clear 2026 Outlook

Despite posting an annual loss, Bayer delivered robust operational performance in the fourth quarter of 2025. Revenue of €11.44 billion exceeded expectations, and earnings per share of €0.62 substantially outperformed the consensus estimate of approximately €0.32.

Looking ahead, management forecasts 2026 revenue in a range of €45 to €47 billion, with adjusted earnings per share expected between €4.30 and €4.80. Furthermore, the potential divestment of the Consumer Health unit, home to brands like Aspirin, remains a possibility. Such a move could generate additional capital to accelerate debt reduction efforts.